NICE says nay to Sprycel, yea to discounted Tasigna

The U.K.'s cost-effectiveness watchdog rejected Bristol-Myers Squibb's ($BMY) Sprycel for chronic myeloid leukemia, but accepted Novartis' ($NVS) Glivec and its follow-up drug Tasigna after the Swiss drugmaker offered a discount on the latter. Report